Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.

Cancer chemotherapy and pharmacology - 1 Jul 2024

Lee In Hee, Lee Soo Jung, Kim Juhyung, Lee Yoon Hee, Chong Gun Oh, Kim Jong Mi, Lee Juhun, Lee Nan Young, Park Seo Young, Hong Dea Gy, Chae Yee Soo

Abstract excerpt

OBJECTIVE: BRCA1/2 are integral to the DNA repair mechanism and their germline pathogenic variants (gBRCA) result in a high risk for developing breast and ovarian cancer. Patients with gBRCA mutations showed increased sensitivity to DNA cross-linking agent but might have increased treatment-related toxicities. Thus, we hypothesized that gBRCA mutation ovarian cancer patients who underwent platinum-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Germ-Line Mutation

Share to Hematologic Diseases

Share to Ovarian Neoplasms

Share to Thrombocytopenia

Source

Identifiers

PMID: 38652271
DOI: 10.1007/s00280-024-04670-8

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.PMID 38652271Read ↗

Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based ChemotherapySemantic proximity Read ↗

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.Semantic proximity Read ↗

g BRCA1 and g BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.Semantic proximity Read ↗

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsSemantic proximity Read ↗

Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.Semantic proximity Read ↗

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapySemantic proximity Read ↗

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcomeSemantic proximity Read ↗

The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.Semantic proximity Read ↗

Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?Semantic proximity Read ↗

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.Semantic proximity Read ↗

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.